<unk>  vaccination within three days of exposure will prevent or significantly lessen the severity of<unk>  symptoms in the vast majority of people. Vaccination four to seven days after exposure can offer some protection from disease or may modify the severity of the disease. Other than vaccination, treatment of<unk>  is primarily supportive, such as wound care and infection control, fluid therapy, and possible ventilator assistance. Flat and hemorrhagic types of<unk>  are treated with the same therapies used to treat shock, such as fluid resuscitation. People with semi-confluent and confluent types of<unk>  may have therapeutic issues similar to patients with extensive skin burns. In July 2018, the Food and Drug Administration approved tecovirimat, the first drug approved for treatment of<unk> . Antiviral treatments have improved since the last large<unk>  epidemics, and studies suggest that the antiviral drug cidofovir might be useful as a therapeutic agent. The drug must be administered intravenously, and may cause serious kidney toxicity. ACAM2000 is a<unk>  vaccine developed by Acambis. It was approved for use in the United States by the U.S. FDA on August 31, 2007. It contains live vaccinia virus, cloned from the same strain used in an earlier vaccine, Dryvax. While the Dryvax virus was cultured in the skin of calves and freeze-dried, ACAM2000s virus is cultured in kidney epithelial cells (Vero cells) from an African green monkey. Efficacy and adverse reaction incidence are similar to Dryvax. The vaccine is not routinely available to the US public; it is, however, used in the military and maintained in the Strategic National Stockpile. In June 2021, brincidofovir was approved for medical use in the United States for the treatment of human<unk>  disease caused by variola virus.
Smallpox
Monkeypox
Cowpox
Impetigo
Chickenpox
Sealpox
Molluscum contagiosum
Mumps